Aim: Dosimetric analysis of three different Radiotherapy techniques in patients with Breast Cancer and their impact on OAR's. Materials and Methods: 12 patients of Carcinoma Breast who received breast radiotherapy were selected for analysis. Computed tomography (CT) simulation image data sets were retrieved. Planning target Volume (PTV), heart and ipsilateral lung were contoured for planning and analysis of doses. Three different plans using conventional bi-tangential fields were prepared, Plan 1 with SAD full beam with wedge (SAD-FBW), Plan 2 with SSD half beam with wedge (SSD-HBW) and plan 3 with SSD half beam without wedge techniques (SSD-HBO) in CMS Xio TPS. Statistical analysis was done using SPSS version 16.0. Results: The PTV coverage was significantly better in SAD-FBW techniques when compared with the other two techniques i.e. SSD-HBW (mean = 92.33, SD = 4.69, p = 0.005) and SSD-HBO (mean = 75.05, SD = 11.92, p = 0.002). The mean heart doses were significantly better in SAD-FBW compared to SSD-HBW (mean = 3.75, SD = 2.27, p = 0.017) but in SSD-HBO technique mean heart doses were better than SAD-FBW technique (mean = 3.27, SD = 1.94, p = 0.004). Similarly, the left lung V20 values were significantly better in SSD-HBO technique than SAD-FBW technique (mean = 11.75, SD = 4.34, p = 0.004) but there was statistically insignificant difference between the SAD-FBW and SSD-HBW techniques.
Background: Pathologic complete response (pCR) is known to be a predictive marker for favorable outcome after neoadjuvant treatment in HER2 positive (þ) breast cancer. Our aim was to investigate the association between hormone receptor (HR) or tumorinfiltrating lymphocytes (TILs) and pCR in HER2 (þ) breast cancer treated with dual anti-HER2 therapy. Methods: Ninety-four patients with HER2 (þ) breast cancer who received neoadjuvant treatment with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) were included in this retrospective analysis. Associations between TILs and pCR were assessed in the overall and hormone receptor (HR) positive (þ) and HR negative (-) populations. We classified subgroups with a cutoff value of stromal TILs (20% TILs vs > 20% TILs) based on ROC curves. Results: Of the 94 cases, 54 (57.4%) tumors achieved pCR (ypT0/is N0) and median TILs was 17.07% [13.81-20.65]. In analysis of hormone receptor, pCR was 51.0% (n ¼ 26/51) in HR (þ) group and 65.1% (n ¼ 28/43) in HR (-) group (p ¼ 0.167). The pCR rate was higher in the high TILs group than in the low TILs group (74.1% vs 51.4%, p ¼ 0.038). In HR (-) group, high TILs and low TILs achieved 90% (n ¼ 9/10) and 57.6% (n ¼ 19/33) of pCR, respectively. In HR (þ), pCR rates of high TILs and low TILs subgroups were 64.7% (n ¼ 11/17) and 41.7% (n ¼ 15/34). Conclusions: In HER2 (þ) breast cancer, HR (-) and high TILs showed higher pCR compared with HR(þ) and low TILs. TILs might be a predictive marker for the treatment response to neoadjuvant dual anti HER2 based chemotherapy. Further investigation in a larger cohort of samples is needed to validate these results. Legal entity responsible for the study: Asan Medical Center. Funding: Has not received any funding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.